Cargando…

Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model

Therapeutics designed to target α-synuclein (α-syn) aggregation may be critical in halting the progression of pathology in Parkinson’s disease (PD) patients. Nanobodies are single-domain antibody fragments that bind with antibody specificity, but allow readier genetic engineering and delivery. When...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Diptaman, Bhatt, Mansi, Butler, David, De Genst, Erwin, Dobson, Christopher M., Messer, Anne, Kordower, Jeffrey H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105584/ https://www.ncbi.nlm.nih.gov/pubmed/30155513 http://dx.doi.org/10.1038/s41531-018-0062-4

Ejemplares similares

Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ
por: Butler, David C., et al.
Publicado: (2016)

Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9
por: Chatterjee, Diptaman, et al.
Publicado: (2021)

α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
por: Butler, Yemima R., et al.
Publicado: (2022)

Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species
por: Iljina, Marija, et al.
Publicado: (2017)

In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain
por: Killinger, Bryan A., et al.
Publicado: (2022)

Proteasome impairment by α-synuclein
por: Zondler, Lisa, et al.
Publicado: (2017)

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome
por: Suzuki, Genjiro, et al.
Publicado: (2020)

Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
por: Lin, Chin-Hsien, et al.
Publicado: (2017)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
por: Tofaris, George K.
Publicado: (2022)

Immunological features of α-synuclein in Parkinson's disease
por: Roodveldt, Cintia, et al.
Publicado: (2008)

Reelin Alleviates Mesenchymal Stem Cell Senescence and Reduces Pathological α-Synuclein Expression in an In Vitro Model of Parkinson’s Disease
por: Cho, Eunju, et al.
Publicado: (2021)

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin
por: Kam, Tae-In, et al.
Publicado: (2022)

Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
por: Wang, Rui, et al.
Publicado: (2022)

Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room
por: Killinger, Bryan A., et al.
Publicado: (2019)

Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys
por: Alarcón-Arís, Diana, et al.
Publicado: (2020)

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis
por: van den Berge, Simone A., et al.
Publicado: (2012)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease
por: Yang, Yunseon, et al.
Publicado: (2022)

Nanobody-Directed Specific Degradation of Proteins by the 26S-Proteasome in Plants
por: Baudisch, Bianca, et al.
Publicado: (2018)

Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's disease
por: Guhathakurta, Subhrangshu, et al.
Publicado: (2021)

A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol
por: Gerdes, Christoph, et al.
Publicado: (2020)

Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson's disease
por: Gou, De-Hai, et al.
Publicado: (2020)

Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype
por: Labrador-Garrido, Adahir, et al.
Publicado: (2014)

A Cellular Model To Monitor Proteasome Dysfunction by α-Synuclein†
por: Nonaka, Takashi, et al.
Publicado: (2009)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease
por: Fitzgerald, Emily, et al.
Publicado: (2019)

Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?
por: Zaltieri, Michela, et al.
Publicado: (2015)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
por: Sekigawa, Akio, et al.
Publicado: (2015)

Functionally different α-synuclein inclusions yield insight into Parkinson’s disease pathology
por: Raiss, Christian C., et al.
Publicado: (2016)

Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
por: Bi, Mingxia, et al.
Publicado: (2021)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Alpha-Synuclein Autoimmune Decline in Prodromal Multiple System Atrophy and Parkinson’s Disease
por: Folke, Jonas, et al.
Publicado: (2022)

An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation
por: Rohner, Eduarde, et al.
Publicado: (2021)

Salidroside Promotes the Pathological α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells
por: Li, Tao, et al.
Publicado: (2018)

Proteasome inhibition alleviates prolonged moderate compression-induced muscle pathology
por: Siu, Parco M, et al.
Publicado: (2011)

PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and α-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease
por: Liu, Wencheng, et al.
Publicado: (2009)

Structure of a Single-Chain Fv Bound to the 17 N-Terminal Residues of Huntingtin Provides Insights into Pathogenic Amyloid Formation and Suppression
por: De Genst, Erwin, et al.
Publicado: (2015)

Clinical Neuropathology image 5-2014: α-synuclein pathology in the ependyma in Parkinson’s disease
por: Kovacs, Gabor
Publicado: (2014)

Chaperone proteins as ameliorators of α-synuclein-induced synaptic pathologies: insights into Parkinson’s disease
por: Banks, Susan M.L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o05npfko1845rpdr3rggmgughv